Morphinsulfat Hexal (Morphine Sulfate)

Morphine sulfate is used as an opioid analgesic for conditions involving severe pain.

• Severe acute pain: provides rapid and potent analgesia for intense pain episodes such as traumatic injuries, severe burns, or acute medical crises.
• Chronic cancer pain: offers sustained opioid control for persistent nociceptive and neuropathic pain associated with malignant tumors, improving quality of life in oncology patients.
• Post‑operative pain: reduces pain intensity after surgical interventions, facilitating early mobilization and recovery while minimizing the need for additional analgesics.

• Morphine sulfate exerts its effect by binding as an agonist to the μ‑opioid receptors located in the central nervous system, particularly in the brainstem and spinal cord. Activation of these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, leading to decreased neuronal excitability and suppression of pain signal transmission. The resultant analgesia is accompanied by sedation and respiratory depression at higher concentrations.

Morphine sulfate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Constipation: reduced gastrointestinal motility leading to hard stools.
• Nausea and vomiting: stimulation of the chemoreceptor trigger zone.
• Drowsiness or sedation: central nervous system depression.
• Dizziness or light‑headedness: orthostatic changes.
• Dry mouth: decreased salivary secretion.

Serious or Rare Side Effects

• Respiratory depression: marked reduction in breathing rate that can be life‑threatening.
• Severe hypotension: sudden drop in blood pressure causing faintness.
• Adrenal insufficiency: impaired cortisol production with prolonged use.
• Anaphylactic reaction: rare but potentially fatal allergic response.

When prescribing morphine sulfate, clinicians should observe several precautionary measures to ensure safe use.

• Assess pain severity and opioid tolerance: determine the appropriate initial dose based on individual needs.
• Monitor respiratory function: observe for signs of respiratory depression, especially during dose titration.
• Evaluate for opioid dependence or abuse risk: screen patients with a history of substance misuse.
• Adjust dose in renal or hepatic impairment: reduce dosage or increase dosing interval as needed.
• Avoid concomitant CNS depressants: limit use with benzodiazepines, barbiturates, or alcohol.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Morphine sulfate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, barbiturates, alcohol): additive respiratory depression.
• MAO inhibitors (e.g., phenelzine, tranylcypromine): risk of severe hypertension or serotonin syndrome.
• Other opioids (e.g., fentanyl, oxycodone): cumulative opioid effect leading to overdose.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase morphine plasma levels.
• SSRIs or SNRIs (e.g., sertraline, duloxetine): potential for serotonin syndrome.
• Diuretics (e.g., furosemide): may enhance hypotensive effect.